<DOC>
	<DOCNO>NCT01030718</DOCNO>
	<brief_summary>To assess safety dasatinib ( BMS-354825 ) subject Imatinib resistant intolerant chronic myelogenous leukemia ( CML ) Philadelphia chromosome positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) resistant intolerant treatment continue study drug complete previous Phase I/II study ( CA180031/NCT00337454 )</brief_summary>
	<brief_title>Rollover Study BMS-354825 Patients With CML Ph+ALL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Subjects eligible complete previous Phase I II study ( CA180031/NCT00337454 ) principal investigator deem continuation study drug best interest subject Women pregnant breastfeed Subjects eligible willing undergo transplantation prestudy Nonhematologic intolerance Dasatinib ( BMS354825 ) previous Phase I II study ( CA180031/NCT00337454 )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>